Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 11/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22808207 | 0.85 | P2RX4 (0.57) | P2RX4P2RX1P2RX3MAPTSMN1; SMN2 | |
| SCHEMBL26119913 | 0.82 | P2RX4 (0.52) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL26113765 | 0.80 | P2RX4 (0.57) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL26118610 | 0.77 | P2RX4 (0.47) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL30571529 | 0.75 | P2RX4 (0.50) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL26120103 | 0.75 | P2RX4 (0.50) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL26631769 | 0.74 | P2RX4 (0.49) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL26631844 | 0.74 | P2RX4 (0.52) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL26631779 | 0.71 | P2RX4 (0.48) | P2RX4BCHEP2RX1P2RX3MAPT | |
| SCHEMBL12955618 | 0.68 | BCHE (0.41) | P2RX4BCHEP2RX1P2RX3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870646-B2 | Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis | UNIVERSITY OF ST. THOMAS (US) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870646-B2 | Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis | OXA1L, IMMT, TBCD | P2RX4 4491/4885BCHE 4150/4885P2RX1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.